4.7 Article

Roflupram protects against rotenone-induced neurotoxicity and facilitates alpha-synuclein degradation in Parkinson's disease models

Journal

ACTA PHARMACOLOGICA SINICA
Volume 42, Issue 12, Pages 1991-2003

Publisher

NATURE PUBL GROUP
DOI: 10.1038/s41401-021-00768-4

Keywords

Parkinson's disease; alpha-synuclein; SIRT1; rotenone; roflupram; lysosome; Sirtuin 1; pepstatin A

Funding

  1. Guangdong Basic and Applied Basic Research Foundation [2021A1515011133]
  2. Science and Technology Program of Guangzhou [202002030494]
  3. National Natural Science Foundation of China [81773698, 81974501]
  4. Key-Area Research and Development Program of Guangdong Province [2018B030334001]
  5. Program for Changjiang Scholars and Innovative Research Team in University [IRT_16R37]

Ask authors/readers for more resources

The research demonstrates that ROF can significantly attenuate cell apoptosis and reduce the level of alpha-syn in ROT-treated cells. Furthermore, ROF enhances lysosomal function through increasing NAD(+)/NADH and the expression of sirtuin 1 (SIRT1).
We have previously shown that roflupram (ROF) protects against MPP+-induced neuronal damage in models of Parkinson's disease (PD). Since impaired degradation of alpha-synuclein (alpha-syn) is one of the key factors that lead to PD, here we investigated whether and how ROF affects the degradation of alpha-syn in rotenone (ROT)-induced PD models in vivo and in vitro. We showed that pretreatment with ROF (10 mu M) significantly attenuated cell apoptosis and reduced the level of alpha-syn in ROT-treated SH-SY5Y cells. Furthermore, ROF significantly enhanced the lysosomal function, as evidenced by the increased levels of mature cathepsin D (CTSD) and lysosomal-associated membrane protein 1 (LAMP1) through increasing NAD(+)/NADH and the expression of sirtuin 1 (SIRT1). Pretreatment with an SIRT1 inhibitor selisistat (SELI, 10 mu M) attenuated the neuroprotection of ROF, ROF-reduced expression of alpha-syn, and ROF-increased expression levels of LAMP1 and mature CTSD. Moreover, inhibition of CTSD by pepstatin A (20 mu M) attenuated ROF-reduced expression of alpha-syn. In vivo study was conducted in mice exposed to ROT (10 mg.kg(-1).d(-1), i.g.) for 6 weeks; then, ROT-treated mice received ROF (0.5, 1, or 2 mg.kg(-1).d(-1); i.g.) for four weeks. ROF significantly ameliorated motor deficits, which was accompanied by increased expression levels of tyrosine hydroxylase, SIRT1, mature CTSD, and LAMP1, and a reduced level of alpha-syn in the substantia nigra pars compacta. Taken together, these results demonstrate that ROF exerts a neuroprotective action and reduces the alpha-syn level in PD models. The mechanisms underlying ROF neuroprotective effects appear to be associated with NAD(+)/SIRT1-dependent activation of lysosomal function.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available